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Core histone variants such as H2A.X and H3.3 serve specialized roles in chromatin 
processes that depend on the genomic distributions and amino acid sequence differences 
of the variant proteins. Modifications of the variants alters interactions with other 
chromatin components and thus the protein’s functions. Similarly, growing evidence 
suggests that amino acid sequence variance also modifies the functions of H1 linker 
histone family members, altering their effects on transcription, differentiation and 
development. These data are contrary to the notion that linker histones are redundant 
repressors. For example, complete loss of H1 does not result in an overall increase in 
transcription, implying that not all H1 variants are associated with repression. 
Furthermore, certain modifications of H1 variants can confer distinct roles. On the one 
hand, phosphorylation of H1 reportedly results in its release from chromatin and 
subsequent transcription of HIV-1 genes. On the other hand, recent evidence has shown 
that the phosphorylated H1 may in fact be associated with active promoters. This conflict 
suggests that different H1 isoforms may play distinct functional roles. Here, we provide 
the first genome- wide evidence that when phosphorylated, H1.4 remains associated with 
active promoters and may even play a role in transcription activation.  
Using novel, highly specific antibodies, we generated the first genome-wide view of the 
H1.4 isoform phosphorylated at serine 187 (pS187-H1.4) in estradiol-inducible MCF7 
cells. We observe that pS187-H1.4 is enriched primarily at the transcription start sites 
(TSSs) of genes activated by estradiol treatment, and depleted from those that are 
repressed. We also show that pS187-H1.4 strongly associates with ‘early estrogen 




Based on observations presented here, we propose that interphase phosphorylation at 
S187 by CDK9 represents an early event required for gene activation. This event may 
also be involved in release of promoter proximal polymerases to begin elongation by 
interacting directly with the polymerase or other parts of the transcription machinery. 
Although we focused on estrogen- responsive genes, taking into account previous 
evidence of H1.4 enrichment at promoters of pluripotency genes, we propose that H1.4 
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CHAPTER 1: INTRODUCTION 
1.1 Linker histone and Chromatin Dynamics 
Repetitive units of histone proteins and DNA called nucleosomes make up eukaryotic 
chromatin. A single nucleosome consists of a core of histone proteins namely, H2A, 
H2B, H3 and H4 and a ~146bp stretch of DNA wraps around this histone octamer 1.7 
times in a left-handed superhelical turn. A fifth protein, a linker protein- H1 binds at the 
entry/exit point of the core histone protein bound nucleosomal DNA alternatively 
referred to as the nucleosomal dyad. This H1 bound nucleosome particle is now referred 
to as a ‘chromatosome’ [1-3]. In early H1 in-vitro work, micrococcoal nuclease (MNase) 
digested soluble chromatin from nuclei was used to study the H1 enriched versus 
depleted DNA. The varying rates of dissociation of core histone and linker histones based 
on ionic strength allowed an insight into the physical properties of chromatin. Depletion 
of linker histones led to decondensation of chromatin and a decreased sedimentation 
velocity [4, 5]. In linker histone containing DNA, an extra ~20bp of DNA was found to 
be protected from MNase digestion in addition to the 146bp of nucleosomal DNA. 
Additional studies demonstrating that the globular domain of H1 localized to the 
nucleosomal dyad, effectively sealing two complete turns of DNA around the 
nucleosome, provided a rationale of the structural role of H1 in chromatin architecture [3, 
6, 7].  
The involvement of H1 in higher order chromatin formation came from electron 
microscopy studies where chromatin folding progressing through rising ionic strength 
was measured. A comparison of H1 containing and depleted chromosomes showed that 




presence of H1. Depletion of H1 not only resulted in a less condensed form of chromatin 
but also resulted in a randomized entry/exit point of nucleosome DNA[8]. Another study 
where nucleosome reconstitution arrays were used to study the chicken linker histone H5, 
showed that the binding of H5 constrained the nucleosomal dyad region in a way such 
that chromosomal structures indistinguishable from their native form were created [9]. 
Together these studies suggest that, in vitro, H1 is required for the formation and 
stabilization of intermediate to higher order chromatin structures [10].  
1.2 Variant forms of eukaryotic linker histone 
Many higher eukaryotes have multiple single copy non-allelic amino acid sequence 
variants. Humans and mice have 11 H1 variants while C. Elegans, Xenopus laevis and 
Gallus gallus (chicken) have 8, 5 and 7 variants respectively. The 11 human H1 variants 
are further divided into two groups, the somatic variants and the germline specific. The 
somatic variants, namely H1.0, H1.1, H1.2, H1.3, H1.4, H1.5 and H1X are expressed in a 
differential manner across the body. The germline specific variants are H1t, H1T2 and 
HILS1 which are testis-specific and the H1oo which is oocyte-specific. H1 proteins have 
a distinct tripartite structure with a central globular domain that is highly conserved 
whereas the C-terminal domain (CTD) and the N-terminal domain (NTD) have more 
variability [2, 11, 12].   
The mammalian H1 genes that have arisen through gene duplication events, referred to as 
paralogs whereas in two different species are referred to as orthologs (For example; 
Human H1.4 and Mouse H1e). The paralog linker histones showed the highest sequence 
conservation in the globular domain with variable tails especially in a subset of somatic 




corresponding orthologs in different species, the sequence of the tail region was found to 
be highly conserved with minimal regions of variability. hH1.4 and mH1e, for example, 
shared a 93.5% sequence identity. Taken together, the idea that ortholog sequences are 
more conserved than the paralogs gives rise to the rationale behind functional 
significance of the multiple variant and that the variability in the tail regions give rise to 
the functional differences [2, 13]. Another way to classify H1 variants is based on their 
dependence on the cell cycle. Of the seven somatic variants, H1.1-H1.5 are replication 
dependent subtypes with maximum expression observed during the S- phase of the cell 
cycle. The sequence between these variants appear to be more conserved when compared 
to the other variants. These genes are located amongst the core histone variant genes on 
chromosome 6 in humans and chromosome 13 in mice. The replication independent 
variants, H1.0 and H1.X are more diverse in the amino acid sequences. The genes are 
located on chromosome 3 and 22 respectively. The other solitary variant genes are 
located on either chromosome 1 in humans or chromosome 5 in mice [14] [15].   
Ubiquitous expression of some H1 subtypes like H1.1 H1.2 and H1.5 are observed with 
varying content levels across different tissue. H1.0 is highly expressed in terminally 
differentiated cells while H1.1 accumulates in specific tissue types like the liver, spleen, 
kidney etc. Most of these genes are seen to be regulated differently.  The most divergent 
of the H1 variants are the 4 germline specific ones. Somatic H1 proteins are replaced with 
germline specific H1 proteins especially during gametogenesis [16].  
1. 3 Subnuclear distribution of H1 
The non-uniform distribution of H1 protein across the genome was hypothesized based 




Due to the lack of ChIP-grade antibodies, the number of studies that can provide a 
distinctive answer to the genomic distribution of H1 are scarce. Most of the previous 
studies have shown that H1 binding is depleted close to areas of active transcription start 
sites (TSSs). This pattern appeared to be evolutionarily conserved. 
The early studies describing the distribution of H1 were primarily conducted with 
Drosophila melanogaster which has only H1 variant with an ‘all inclusive’ antibody that 
did not differentiate between subtypes. Even though this provided a view of H1 
localization, there was no information about the different subtypes. Dam-ID techniques 
applied on D. melanogaster cell line Kc167, H1 appeared to have similar levels of 
distribution across heterochromatin and euchromatin. The H1 depleted zones coincided 
with active transcription sites and some putative regulatory regions [17-21]. Additionally, 
H3.3, a core histone variant was found to be responsible for gene activation by negatively 
regulating H1 binding. In a breast cancer cell line, MCF7, ChIP was conducted with a 
pan-H1 antibody in conjunction with microarrays studies to show that H1 and PARP-1 
enzymes had reciprocal binding and was associated with gene repression [18]. Another 
ChIP-seq study in Drosophila S2 cells, to compare localization of H1 and some 
chromosomal architectural proteins, namely HMG1 showed a depletion of H1 signal 
around active transcription sites. They also found that in contrast to earlier studies, H1 
was relatively enriched in heterochromatin whereas the HMG-1 was highly associated 
with euchromatin [17]. Tagged versions of H1d and H1c (orthologs of human H1.3 and 
H1.2 respectively) were knocked into mouse embryonic stem cells (mESCs) in 
conjunction with H1.0 overexpression to describe their binding patterns by ChIP-seq. 




pericentromeres and are a more condensed and stable type of chromatin. H1.0 showed 
some similarities with H1c and H1d but was additionally enriched at minor satellite 
repeats and LINE-1 elements [21]. Triple knockout of H1C, H1d and H1e (orthologs of 
Human H1.2, H1.3 and H1.4) resulted in upregulation of major satellite based 
transcription, shorter nucleosome repeat lengths (NRL) and chromocenter clustering [22].  
In an attempt to understand the genome wide distribution of H1, Dam-ID was used in a 
study conducted in lung fibroblasts that describe the distribution of five somatic H1 
variants (H1.1-H1.5). Another study used tagged H1 antibodies and overexpression of 
H1.2 and H1.5 to describe distribution of H1 in breast cancer cell lines. Together these 
studies suggested an uneven distribution of H1 with differential binding amongst the 
variants. The depletion of H1 variants from active transcription sites was reiterated with 
additional depleted sites at CpG islands and active regulator regions identified. H1.1, 
however was found to have a distinctly different binding pattern with enrichment at a few 
‘active’ genomic domains. Comparing these two studies showed that H1 variants 
correlated with genomic regions previously functionally associated with the 3D 
organization of chromatin, gene depleted regions, low GC content and lamina associated 
domains (LADs). The techniques used for these studies, however, have limited resolution 
with Dam-ID unable to describe localization in repetitive elements lacking GATC 
sequences and the risk of non- specific binding when overexpressing the H1 variants [20, 
23]. H1.5 in human embryonic stem cells was found to be strikingly different in its 
distribution compared to that seen in differentiated fibroblasts. Here, H1.5 enrichment 
correlated with transcriptionally silent genomic regions encoding membrane-associated 




were primarily found to be enriched in terminally differentiated cells. H1.0 showed an 
enrichment at nucleolar associated regions whereas H1X, although showed the general 
depletion pattern at active sites was surprisingly found to be associated with RNAPII 
occupied sites [25]. These differences in distribution patterns appear to coincide with 
some functional differences. This suggests that post-translational modifications may 
further contribute to the variability and may be instrumental in elucidating their role in 
genomic organization and regulation. 
1. 4 Posttranslational modifications (PTMs) of H1 
Similar to the core histones and their variants, linker histones also undergo a variety of 
post-translational modifications in the CTD, NTD and the globular domain. 
Phosphorylation of H1 was amongst the earliest modification to be described [26]. But 
more recently, mass spectrometric studies revealed that H1 can undergo a number of 
modifications like methylation, acetylation, ADP ribosylation, ubiquitination, 
formylation and PARylation [27-31]. These findings that were derived from a variety of 
different organisms brought forth the possibility that the histone code hypothesis could 
also be applied to H1 where specific functions could be ascribed to specific modifications 
[32]. In the following sections, some of these modification will be discussed briefly.  
Phosphorylation will be given emphasis as that is the primary focus of this study. 
1.4.1 H1 methylation 
Methylation sites in linker histones have mostly been found within the NTD of H1. For 
example, methylation of H1.4 lysine K26 was found to be the most abundant methylation 
mark on a human linker histone. This modification was also seen in drosophila, 




methylatransferases as part of the PRC2 complex were identified as the enzyme 
responsible for this modification in mammalian cells whereas the removal was carried out 
by JMJD2/KDM4 demethylases. This modification provides the scaffolding for 
heterochromatin associated protein binding like HP1 and L3MBTL1. H1.4K26 was 
demonstrated to be a part of an ‘ARKS’ motif adjacent to a Ser27 which when 
phosphorylated can inhibit HP1 binding. This suggests that a crosstalk between 
modifications might be involved in the functionality of the H1 PTM. G9a/Glp1 
methyltransferase was also shown to catalyze the methylation on different H1 variants at 
specific sites with each of them having different reader suggesting that specific 
methylations may be may have specific functions [34-36].   
1.4.2 Acetylation of linker histones  
Core histone studies have largely attributed opening of chromatin and active transcription 
to acetylation [37]. Similarly, it is likely that H1 acetylation may result in DNA 
conformational changes such that H1 may be displaced. However, the dependence on 
histone deacetylase inhibitors to study this modification results in an occasional inability 
to separate the effects on core histones versus the linker histones.  
The role of H1 acetylation with respect to gene activation was demonstrated where 
acetylation of H1.4K34 was carried out by GCN5- a histone acetyl transferase enzyme. 
This modification was seen to activate transcription by way of TAF1- a TFIID subunit 
recruitment and also by weakening H1 chromatin interaction [38]. The previously 
described H1.4K26 methylation site was also found to be a substrate for acetylation by an 
as yet unidentified acetyltransferase. This acetyl mark is removed by SirT1 [39]. This 




Mutations at this site resulted in serious defects in cell proliferation and regulation of 
specific genes [40]. The use of similar enzymes for acetylation of both the core histones 
as well as the linker histone raises the idea of a possible functional links between the two.  
1.4.3 H1 ubiquitination 
H1 monoubiquitination was described early in 2000 [41] in Drosophila by TAFII250 
which is a subunit of the TFIID transcription factor complex thereby linking it to 
transcription. Other ubiquitination sites in Drosophila, K23, K27 and K165 were more 
recently discovered [33]. H1.5 mono-ubiquitination in mouse HFR(+) cells was found to 
have a possible role in HIV-1 resistance. Mass spectrometric studies have identified more 
mammalian H1 ubiquitination sites in both human cell line and mouse tissues, however 
their function remains to be identified [42].  
1.4.4 H1 ADP-ribosylation 
The transfer of ADP ribose moiety from its co-substrate NAD+ onto specific amino acid 
residues of acceptor proteins by ADP ribosyltransferases (ARTs) results in a covalent 
post translational modification called ADP ribosylation. A mammalian ART, Poly ADP 
ribose polymerases (PARP), PARP1 is one of the better studied enzymes. PARP1 not 
only acts as its own substrate but also targets core histones and H1. PARP3 was found to 
be responsible for ADP ribosylating H1.2 in vitro [43-45].  
1.4.5 H1 Citrunillation 
H1 citrullination occurs by conversion of an arginine to citrulline by peptidylarginine 
deaminases (PADIs). This conversion results in the subsequent loss of positive charge. 




mESCs. Interestingly, citrullination of a single arginine residue H1K54 resulted in the 
removal of H1 and subsequent global chromatin decondensation [46].  
1.4.6 H1 phosphorylation  
H1 phosphorylation was one of the first post translational modification to be identified. It 
has since been well characterized with a variety of functions being associated with it 
depending on its localization. Unlike the previously described PTMs, phosphorylation 
tends to be restricted to the tail regions of H1 where several (S/T)-P-X-(K/R) motifs may 
be found [47]. These motifs are primarily identified by cyclin dependent kinases (CDKs). 
The levels of phosphorylation rise progressively through the cell cycle with the lowest 
levels seen at G1 phase, increasing levels throughout S-phase and G2-phase and a sharp 
spike during mitosis.  
A study conducted on H1.5 showed that serine residues are preferred by kinases for 
phosphorylation during the G1 and the S phase while the threonine residues are preferred 
during mitosis. The kinases predominantly responsible for mitotic H1 phosphorylation 
are CDK1/CycB. Other kinases Aurora B kinase, Protein Kinase A and Glycogen 
synthase- 3 may also carry out mitotic phosphorylation of H1.4S27, H1.4S35 and 
H1.5T10 respectively [48-51]. In contrast to the mitotic phosphorylation, during G1 and 
S phase H1 phosphorylation has been correlated with decondensation of the chromatin. 
This was detected at replication sites where H1 phosphorylation was involved in the 
opening of the chromatin to allow the replication fork progression [52]. Initial studies 
assumed that H1 phosphorylation was linked to mitotic condensation of the chromosomes 
due to the elevated levels observed during this time [53, 54]. Subsequent studies took a 




cells. These cells were unable to enter mitosis as a result of this treatment. These cells 
when treated with nocadazole to arrest in mitotic phase, a subsequent treatment of 
staurosporine resulted in widespread dephosphorylation and chromosome decondensation 
[51, 55].  
Another study used Chinese hamster ovary cells (CHO) and treated them with 
staurosporine as well as Hoechst 33. This prevented both interphase and mitosis 
phosphorylation which resulted in the inability of the G2 chromosomes to condense into 
mitotic chromatin [56].  
In some non- mammalian systems like the highly condensed chromatin of sea urchin, 
mitotic macronuclei of T.thermophilia and terminally differentiated avian erythrocytes, 
H1 phosphorylation was seen to be uncoupled from chromosome condensation. In these 
systems, the condensed forms of chromatin was seen to be enriched with high levels of 
dephosphorylated H1 [57, 58]. This difference could be attributed to the fact that there 
are difference in their CTDs. Some studies have also shown the hyperphosphorylation is 
not a pre-requisite for chromosome condensation during mitosis and that H1 
dephosphorylation may in fact result in a dynamic exchange of H1 which facilitates 
chromosome decondensation [59, 60]. For example, in mouse NIH3T3 cells, H1 
phosphorylation leads to heterochromatin disassembly by disrupting HP1 and H1 
interactions. Based on the above studies, it is clear that mitotic phosphorylation is not 
fully understood and that differences between H1 sequences may be contributing to 
variability in function [61].  
H1 phosphorylation and its numerous effects on chromatin binding gave rise to the idea 




cell. Low levels of DNA damage would result in fewer H1 molecules being released as a 
result of phosphorylation to allow local decondensation of the chromatin and allow DNA 
repair machinery access [62] 
1.4.7 Interphase phosphorylation of H1 
Several studies using mass spectrometry and chromatography described the 
phosphorylation status of H1 based on their abundance and site specificity of 
differentially modified forms during interphase and mitosis. Reverse phase- HPLC was 
used to resolve H1.5 from other variants expressed in asynchronous CCRF-CEM 
lymphoblastic T-cells. This was followed by hydrophilic interaction chromatography 
(HILIC) to resolve individual phosphorylated forms of H1.5 prior to bottom-up MS 
analysis [53]. Major and minor fractions of monophosphorylated H1.5 corresponding to 
phosphorylation at S18 and S173 and single fractions for di- and triphosphorylated H1.5 
were resolved by HILIC suggesting that H1.5 phosphorylation occurs in a hierarchical 
manner from N-terminal to C terminal during interphase. In CCRF-CEM cells, sequential 
phosphorylation at S18, S173 and S189 predominated over S173, S18 and S189. This 
may be a general feature of H1.5 phosphorylation regulation. This was also seen in 
Human Raji and U937 cells, and in mouse F4N erythroleukemic cells [15]. Single RP-
HPLC fractions containing H1.2, H1.3 and H1.4 from CCRF-CEM cells were analyzed to 
reveal H1.2-S173, H1.3-S189, H1.4-S172 and H1.4-S187 as major sites of interphase 
phosphorylation [63]. They also identified specific differences in phosphorylation 
between asynchronously growing cultures (predominantly G1 cells) and colchicine- 
treated mitosis arrested cell cultures. Interphase phosphorylation of H1.5 localized 




consensus motif. The same sites were also phosphorylated in H1.5 from mitotic samples 
but this was now in addition to phosphorylation at T11 which is a non-cdk type site, and 
at T138 and T155, two TPXZ cdk type sites. Analyses of pentaphosphorylated H1.5 from 
mitotic samples showed that two phosphorylation isomers where T11 + S18 + T138 + 
S173 + S189 or T11 + S18 + T155 + S173 + S189 were phosphorylated. This puts for the 
idea that phosphorylation at H1.5-T138 and H1.5-T155 may be mutually exclusive [49]. 
Earlier studies in our lab used hydrophobic interaction chromatography (HIC) 
purification to resolve H1 variants and their phosphorylated forms in a single step prior to 
analysis by top-down mass spectrometry (TDMS). This was done to characterize H1 
extracted from synchronized HeLa cells during different stages of the cell cycle [64]. 
Top down mass spectrometry (TDMS) is used for direct analysis of posttranslational 
modifications on intact histones and other small proteins. This maintains the connectivity 
between sites on multiply modified forms. TDMS studies showed that S173 is the 
predominant, and maybe exclusive, site of interphase phosphorylation on H1.2. Mono 
and diphosphorylated forms of H1.4 were present throughout interphase however, 
interphase monophosphorylation of H1.4 localized exclusively to S187 whereas 
diphosphorylation localized to S187 + S173 [65]. These results suggest that interphase 
phosphorylation of H1.4 proceeds in a C-terminal to N-terminal fashion in HeLa cells. 
This was in contrast to the findings for H1.5. The mechanism(s) and biological 
significance of hierarchical interphase phosphorylation of H1.4 and H1.5, and why they 
differ in directionality are not understood. Taken together H1.2-S173, H1.4-S173, H1.4-
S187, H1.5-S18, H1.5-S173 and H1.5-S189 can be considered the predominant, if not 




cells.  Fluorescence recovery after photobleaching (FRAP) microscopy is widely used to 
describe the chromatin binding dynamics of fluorescent protein fusions of H1 and many 
other proteins in living cells [6]. These studies showed that phosphorylation at of H1 can 
alter its binding properties to chromatin. H1.1- GFP expressed in human cells and H1.0-
GFP or H1c-GFP expressed in mouse cells are significantly more dynamic in chromatin 
compared to core histone GFP fusions. They displayed a short bound time before 
dissociating and rapidly binding again. Multiple studies conducted with GFP-H1 and 
GFP-H1 mutants showed that the H1 CTD is a major determinant of chromatin binding 
by H1. This also agrees with the notion that structural differences in the CTD may give 
rise to functional differences between H1 variants.  
H1-chromatin binding is also affected by the overall nature of the chromatin environment 
and direct competition with other chromatin proteins for binding sites.  For example, cells 
treated with histone deacetylase inhibitor Trichostatin A (TSA), induced global 
hyperacetylation of core histones. This resulted in a more open chromatin state which 
increased the mobility of both H1.0-GFP and H1c-GFP.  
1.4.8 H1 phosphorylation implicated in transcription 
In more recent times, several studies have confirmed a link between H1 and active 
transcription. The current view suggests that phosphorylation of H1 weakens its binding 
affinity to chromatin and it also favors the removal of the H1 from actively transcribing 
genomic regions [66, 67]. One study demonstrated in detail the sequence of events 
occurring during the first minute after hormone induction of MMTV promoter. 
Chromatin remodeling complexes NURF and ASCOM were recruited by the active 




specifically trimethylates H3K4 to stabilize NURF. This action results in Cdk2/CyclinA 
kinase action on H1 which leads to its removal. The depletion of H1 was said to be 
responsible for facilitating transcriptional machinery access for the activation of the 
MMTV promoter [68]. Unfortunately, the antisera used in this work did not reveal 
whether site-specific phosphorylation of particular H1 variants are preferentially 
involved.  
With the advent of genome wide technology, a comprehensive view of the role of 
interphase H1 phosphorylation in transcription or how the distributions of specific 
interphase phosphorylations can be superimposed on the genomic distributions of the H1 
variants. However, due to the paucity of site-specific ChIP-grade antisera other strategies 
were employed. 
Ectopic expression of H1 variants fused to epitope tags or the Dam DNA 
methyltransferase followed by genome-wide analyses were carried out. The findings 
suggest that H1 variants, overall, are depleted from active promoters [20, 69]. However, 
these studies also revealed an unexpected array of differences in the distributions of 
certain variants.  The Dam-ID study showed variant-specific patterns of enrichment and 
depletion across the genome for each of the analyzed variants. H1.1 distribution was 
vastly different from H1.2–H1.5. HA-tag fusions of H1.0, and H1.2–H1.5, and 
endogenous H1.2 and H1.X distributions were comparatively analyses revealing a 
distinct but overlapping fashion [23, 25]. The degree of depletion relative to activity at 
promoters differed between them. H1.2 was seen to associate with repressed promoters 
and lamina-associated domains to a larger extent as compared to the other subtypes. 




distribution of H1.5. When depleted, differentiated cells show a loss of repressive 
chromatin marks, chromatin accessibility increased and deregulation of gene expression 
was seen. This suggests a specific role of H1.5 in the repression of defined gene families 
in differentiated cells [24].  
 In another study, gene-specific changes in transcription was observed in triple H1 variant 
knockout mouse cells. This is consistent with the possibility that differences in interphase 
phosphorylation are involved in determining the differential effects of individual H1 
variants on transcription. However, genome-wide distribution data to addresses this issue 
was not yet available any interphase phosphorylated H1 variant [70].  
In earlier studies from our lab, immunofluorescence revealed extensive co-localization of 
staining for H1.2/5-S173 phosphorylation with BrUTP labeling in HeLa and HEK293 
cells. On the other hand, pH1.5-S18 staining did not co-localize with BrUTP foci in HeLa 
cells. This suggests that H1.5-S18 phosphorylation may be involved in other cellular 
process rather than transcription. ChIP-qRTPCR studies conducted in our lab showed that 
H1.4-S187 phosphorylation is enriched at estrogen and glucocorticoid hormone response 
elements shortly after hormone stimulation in multiple cell lines, suggesting that pS187-
H1.4 facilitates gene-specific activation of Pol II transcription by nuclear hormone 
receptors.  Immunofluorescence microscopy also revealed a role for interphase H1 
phosphorylation in transcription of rDNA by RNA pol I. Intense clusters of punctate 







CHAPTER 2: H1 ANTIBODY PURIFICATION AND VALIDATION 
 
2.1 Introduction  
In previous studies from our lab, H1 antisera previously developed against whole 
recombinant protein and peptides were used to describe the function and role of H1 in a 
number of different scenarios [64, 71]. These studies used the antisera in its crude form 
but were effective in their application in some biochemical methods like western blotting, 
immunofluorescence and ChIP-PCR. However, to expand the scope of our study, the 
need to study H1 on a genome- wide basis became important. We observed that the 
antisera, in its crude form, was not efficient for ChIP-seq and the pulldown of DNA 
required the use of a larger number of cells and in the case of pan-H1.4, it appeared that 
there was little to no pulldown.  
In order to correct this, we developed a modified version of the standard affinity 
purification protocol [72]. This purification protocol was applied to multiple H1 antisera 
namely panH1.0, panH1.4, pan-H1.5, pS187-H1.4 and pS18-H1.5. Following purification 
and concentration of the antisera, validation for specificity was carried out as per 
ENCODE guidelines.  
2.2 Antisera purification  
2.2.1 Protein biotinylation 
In order to prepare the column for affinity purification the H1 proteins were biotinylated. 
This method allows for efficient binding of the protein to the streptavidin coated resin 
beads which are used to make up the purification column. To achieve defined, low level 




affinity purification of antisera with minimal modification of the epitopes that confer H1 
variant-specific binding, the following setup was followed. 
Reagents: 1) Recombinant H1 variant. Lyophilized from RP-HPLC buffer. 2) 10 mM 
NHS-biotin in DMSO. 2 mg NHS-biotin powder dissolved in 590 ul DMSO. Purchased 
as a powder (Apex Bio) and stored in a sealed bag with dessicant at -20C. Moisture and 
light sensitive. Allow to come fully to room temp before opening. Rapid hydrolysis in 
aqueous solutions competes with protein biotinylation and is the main factor limiting 
efficiency. It was critical to use relatively new NHS-biotin and prepare the DMSO stock 
just before use and shield from light. 3) PBS: 100 mM sodium phosphate, 150 mM NaCl, 
pH 7.2. 4) 100 % w/v TCA, 5) 20 % TCA (freshly diluted from 100 % with dH2O) 6) 
acetone/0.1 % HCl acetone. 
The quantities specified here were used primarily to establish reaction conditions. Once 
optimal conditions were known, volumes of the reactants were scaled up linearly to 
provide sufficient material to make 1 ml affinity columns. Here we rely on TCA 
precipitation to remove free biotin prior to assaying the extent of biotinylation of H1 in 
the assay below. Briefly, 50 ug of dry H1 variant was dissolved in 50 ul PBS and cooled 
on ice for at least 10 min. 9 ul of 10 mM NHS-biotin was added, triturated to mix, and 
continued incubation on ice. 10 ul samples were transferred to new tubes at 30, 60, 90 
and 120 min. Each sample was brought up to 20 % TCA (final) by adding 2.5 ul of 
100 % TCA and 40 ul of 20 %. Samples were kept on ice until the last sample 
precipitated for at least 1 hour. Spin tubes for 5 min at 13K in 4C microfuge to pellet the 
H1. Pour off the supernatant and invert tubes on a paper towel briefly to drain residual 




supernatant as above. Wash pellets 1x with 1 ml acetone/0.1% HCl, and 2X with 1 ml of 
100 % acetone. Pellets of purified H1 typically do not stick to the tube wall once they are 
washed with acetone. Allow tubes to air dry to evaporate residual acetone. Each pellet 
was dissolved in 20 ul of dH2O. 10 ul from each tube was used in a micro-assay to 
quantitate biotinylation assay. The Pierce biotin quantitation kit (Thermo cat # 28005) kit 
was used for this purpose and the manufacturer’s protocol were used to carry out the 
assay. The ratio of biotin/H1 was calculated as specified in the manual.  
2.2.2 Column preparation   
The volumes and quantities used are for 1 ml columns. These can be scaled up or down 
as needed. The materials required were as follows: 1) Streptavidin-agarose (Genscript 
L00353), approximately 2 mg of streptavidin per ml of settled crosslinked 4 % agarose 
beads. Capacity approx. 30 ug or more of D-biotin/ml settled beads. The actual capacity 
for biotinylated peptides and proteins depends on their MW and steric factors. 
For small phosphopeptides used as antigens (e.g. 9 residues) that have been synthesized 
with biotin-Ahx at the N-terminus for use in purification, the capacity is approx.120 ug 
biotin-Ahx-peptide/ml settled gel. Use at least 2X this amount to ensure that the 
streptavidin is saturated when preparing supports. For full length H1 variants that have 
been biotinylated at 2-4 lysines/molecule (expected avg MW approx. 22,500 Da), the 
capacity may be as high as 470 ug of H1 assuming steric hindrance is not an issue. Until 
we know more about the latter, aim to bind 0.5 mg of biotinylated H1 per ml of settled 
resin. 2 ) PBS (freshly prepared) 20 mM phosphoric acid, 150 mM NaCl, adjusted to pH 
7.2 with NaOH 3) 100 mM glycine, adjusted to pH 2.5 with HCl (freshly prepared)  4) 




The method used is as follows: Set up a small (1 cm diam.) chromatography column and 
pipette 2 ml of PBS into it. The streptavidin-agarose is supplied as a 50 % slurry in PBS 
containing 20 % ethanol (5 ml settled resin in total volume of 10 ml). Invert the bottle 
several times to make the slurry homogenous. Transfer the volume needed to the empty 
column using a pipette with a wide diameter orifice and allow the resin to settle on the 
exit frit (use 2 ml slurry for a 1 ml column). Drain excess PBS/ethanol and then wash the 
bed with 5-10 volumes of PBS. Drain excess PBS and cap exit. Apply the desired amount 
of biotinylated peptide/protein (see guidelines above) in 1 ml PBS and allow to enter bed. 
Cap exit and allow binding to proceed for 10 min at RT. Carefully apply 1 ml of PBS to 
bed, uncap exit and collect the next 1 ml. Cap exit. To ensure all target is bound, re-apply 
the collected 1 ml to the column, allow to enter the bed, cap exit and incubate a further 10 
min. Then wash the column with 10 volumes of PBS.  Remove any loosely bound target 
molecules before using the column by eluting with 10 volumes of elution buffer. Re-
equilibrate with PBS. Columns can be stored for a month, and possibly longer, at 4oC in 
PBS containing 0.05 % NaN3 to inhibit microbial growth. For phosphopeptide columns, 
the stability of the phosphorylated residue is the critical, unknown, factor.  
2.2.3. Antisera Purification 
Crude animal sera contains high concentrations of serum albumin that typically interferes 
with antibody binding to immobilized antigens. In addition, serum is rich in proteases, 
phosphatases and other activities that may degrade immobilized antigens. Many protocols 
for affinity purification suggest that diluting animal sera 2-10 fold with buffer is 
sufficient to promote efficient antibody binding to columns. However, this has not been 




dilution increases loading times significantly, and dilution does not address the issue that 
some serum components may degrade columns. We recommend depleting serum 
preparations of albumin and other unwanted proteins using precipitation with 50 % 
(NH4)2SO4 prior to chromatography (see protocol). Performed properly, a single 
precipitation is sufficient. Reconstitute the “gamma globulin” precipitate in PBS (same 
volume as the original serum volume), clarify by centrifugation or syringe filtration if 
necessary, and apply directly to the column. Desalting to remove residual (NH4)2SO4 is 
not necessary. Column loading can be performed at RT to maximize antibody affinity. 
However, subsequent washing and elution steps should be performed using chilled (4 ֯C) 
buffers and fractions kept on ice to minimize antibody denaturation. If the column has 
been stored, wash with 5 volumes PBS. Drain excess PBS and apply the clarified gamma-
globulin sample to column. Collect the flow-through and reapply to column. Repeat 
loading at least 3 times. Wash column with 10 volumes of PBS. Elute column with 20 
volumes of PBS-500 (removes low affinity, non-specific antigen binding). Elute column 
with 15 volumes 100 mM glycine, pH 2.5. Collect fractions sequentially on ice into the 
tubes containing 1M Tris pH 8.8. Use pH strips to confirm that each tube is pH 7.5 and 
adjust if necessary. Wash column with 20 volumes PBS. Confirm eluate is pH 7.2 before 
proceeding. Elute column with 15 volumes 100 mM triethylamine, pH 11.5. Collect 
fractions sequentially on ice into the tubes containing 1M Tris pH 6.8. Use pH strips to 
confirm that each tube is pH 7.5 and adjust if necessary. Wash column with 20 volumes 
of PBS. Continue to eluate if necessary to reach pH 7.2 before proceeding. Store column 
in PBS containing 0.5. % NaN3.  Determine which fractions contain antibody. (Bradford 




equilibrated with PBS. Assay protein concentration (A280). Concentrate if necessary to 
attain 1-2 mg ml. Antibody activity is lost much more rapidly due to denaturation and 
adsorption to tube walls when they are stored at less than 1 mg/ml, regardless of storage 
temp. If you do not need to conjugate the antibodies, add high quality (protease and 
immunoglobulin-free) BSA to 1 mg/ml final.  Storage conditions depend on what will be 
done next. If the antibodies will be labeled with fluorochromes, add thimerosal to 0.01 %, 
store at 4oC, and initiate the labeling as soon as possible. Alternatively, working aliquots 
for blotting, regular IF, etc. can be made 0.05 % NaN3 and stored at 4oC. For long term 
storage, aliquot into 0.5 ml screw top tubes, seal aliquots well with parafilm, snap-freeze 
in liquid nitrogen and store at -80֯C.  
2.3 Validation of purified antibodies 
In order to ensure that the purified antibodies were specific, three cell types- HeLa, 
mESC and MCF7 cells were used. Overall, the punctate staining obtained with the pan-
H1.4 antisera (generated against full length recombinant human H1.4) in IF microscopy 
suggests that chromatin bound by H1.4 is distributed nonuniformly throughout the nuclei 
of all 3 cell types (Figs. 2.1, 2.2, 2.5, 2.6, 2.7 and 2.8). This is an entirely novel finding 
that is unlikely to be an artifact since we have shown previously that the antisera is highly 
specific for human and mouse H1.4 in immunoblots of whole cell lysates. Moreover, pan-
H1.4 staining is significantly diminished in all 3 cell types by siH1.4 treatment (Figs. 2.2, 
2.6 and 2.8). Also, siH1.4 treatment significantly reduced the ChIP signal obtained for 
pan-H1.4 in the ChIP experiments we have done since discovering that affinity 




A mixture of diffuse and punctate staining was observed for pS187-H1.4 in all 3 cell 
types, but appears to be morphologically distinct in each case (Figures. 2.1, 2.2, 2.5, 2.6, 
2.7 and 2.8). The conspicuous focal staining we observed previously for pS187-H1.4 in 
NT2 and C2C12 cells is not apparent in untreated MCF7, HeLa or mESCs. FLVP reduces 
diffuse pS187-H1.4 staining, but dramatically enhances focal pS187-H1.4 staining in 
NT2 and C2C12 cells, suggesting that the focal staining in both untreated and FLVP-
treated NT2 and C2C12 cells is due to cross-reactivity of the pS187-H1.4 antisera with 
other (unknown) phosphoproteins. Similar focal staining is observed in MCF7, HeLa and 
mESCs exposed to FLVP, but is not apparent in untreated cells. We suggest that focal 
staining is induced by FLVP in these latter cell types, and that the pS187-H1.4 antisera is 
specific for this epitope in untreated cells. Moreover, cross-reactivity of the pS187-H1.4 
antisera does not appear to be a factor in ChIP analyses since FLVP treatment essentially 
abolishes the pS187-H1.4 ChIP signal in HeLa cells (Figure. 2.5) and mESCs (Figure. 
2.7). The effect of FLVP on pS187-H1.4 ChIP is less dramatic in MCF7 cells (Figure. 
2.3), but we presume that this is explained by our evidence that one or more H1.4-S187 
kinases in addition to CDK9 are expressed in MCF7 cells. 
The ChIP experiments in MCF7 included the ACT and ACTG1 housekeeping genes in 
addition to genes are known targets of estrogen signaling. We presumed that the 
expression of these genes, and their pS187-H1.4 levels would be largely unaffected by 
the standard hormone depletion and estradiol stimulation paradigm employed in these 
experiments. The data shown for the DMSO control samples shown in Figure. 2.2E and  
2.2F are consistent with this, and the pS187-H1.4 signals for both –E2 and +E2 are 




results shown in Figure. 4C and 4F where the pS187-H1.4 levels were enhanced for the 
untreated E2 samples after siH1.4 compared to the siLuc control samples. The basis for 
this discrepancy is unknown. We do not believe it is due to antisera cross-reactivity since 
H1.4 depletion diminished the ChIP signals for pS187-H1.4 as expected in the remaining 
samples in Figure. 2.4. 
In Hela and mESC cells, punctate nuclear staining is observed for pan-H1.4 in these cell 
types but the punctate nature is not as apparent as it is in MCF7 cells due to increased 
numbers of staining dots. In addition, the images presented here are Z-projections of 
stacked images which gives the appearance that neighboring dots fuse to resemble the 




























Figure 2.1 Immunofluorescence of MCF7 cells (nuclei) treated with DMSO/FLVP for 1 
Hour. Panels A-F shows pan-H1.4 staining of nuclei treated with DMSO (A-C) and 
FLVP (D-F). Panels G-L shows pS187-H1.4 staining of nuclei treated with DMSO (G-I) 

















Figure 2.2 Immunofluorescence of MCF7 cells (nuclei) treated with siLuc/siH1.4. Panels 
A-F shows pan-H1.4 staining of nuclei treated with siluc (A-C) and siH1.4 (D-F). Panels 









Figure 2.3 Changes in the levels of pS187-H1.4 at promoters of genes responsive to 
estradiol (E2) (A-D) and housekeeping genes (E-F) as a result of FLVP treatment against 
H1.4 were assessed by ChIP-qPCR. 
 A-B) The levels of pS187-H1.4 at the promoters of P2RY2 and ERBS1 rise as a result of 
estradiol treatment. These levels drop as a result of H1.4 knockdown. C-D) The levels of 
pS187-H1.4 at the promoters of PNRC1 and ERBS4 are repressed as a result of estradiol 
treatment. These levels diminish further as a result of FLVP. E-F) ACTB and ACTG1 
appear to be repressed as a result of estradiol treatment. However, the pS187-H1.4 levels 
at the promoter of ACTB result in a further decrease of signal. pS187-H1.4 appears to 
increase as a result of the H1.4 knockdown but is reduced more than the siluc control 
when induced with estradiol. In all cases, negative control ChIP assays were employed 













Figure 2.4. Changes in the levels of pS187-H1.4 at promoters of genes responsive to 
estradiol (E2) (A-D) and housekeeping genes (E-F) as a result of siRNA treatment 
against H1.4 were assessed by ChIP-qPCR. 
 A-B) The levels of pS187-H1.4 at the promoters of P2RY2 and ERBS1 rise as a result of 
estradiol treatment. These levels drop as a result of H1.4 knockdown. (C-D) The levels of 
pS187-H1.4 at the promoters of PNRC1 and ERBS4 are repressed as a result of estradiol 
treatment. These levels diminish further as a result of siRNA mediated H1.4 knockdown. 
E-F) ACTB and ACTG1 appear to be repressed as a result of estradiol treatment. 
However, the pS187-H1.4 levels at the promoter of ACTB result in a further decrease of 
signal. pS187-H1.4 appears to increase as a result of the H1.4 knockdown but is reduced 
more than the siluc control when induced with estradiol. In all cases, negative control 







Figure 2.5. Panels A-L show immunofluorescent images of HeLa cells treated with 
DMSO/FLVP for 1 hour and stained with pan-H1.4 (A-F) and pS187-H1.4 (G-L). pan-
H1.4 staining was markedly reduced after FLVP treatment (5D) as compared to the 
control- DMSO treated (5A). pS187-H1.4 staining was also reduced (5J) as compared to 
the control (5G) and similar to the MCF7 cells appeared to have accumulated in some 
regions. Levels of pS187-H1.4 at the promoters of ACTG1 and ACTB genes as a result 








Figure 2.6. Panels A-L show immunofluorescent images of HeLa cells treated with 
siRNA against H1.4 for 72 hours and stained with pan-H1.4 (A-F) and pS187-H1.4 (G-
L).  The pan-H1.4staining was markedly reduced after siH1.4 knockdown (6D) as 
compared to the control- siLuc (6A). The pS187-H1.4 staining was also reduced (6J) as 
compared to the control (6G) and similar to the MCF7 cells and the HeLa-FLVP 
treatment appeared to have accumulated in some regions. Levels of pan-H1.4 and pS187-
H1.4 at the promoters of ACTG1 and ACTB genes as a result of siH1.4 show a marked 







Figure 2.7. Panels A-L show immunofluorescent images of mESC cells treated with 
siRNA against H1.4 for 72 hours and stained with pan-H1.4 (A-F) and pS187-H1.4 (G-
L).  The pan-H1.4staining was markedly reduced after siH1.4 knockdown (6D) as 
compared to the control- siLuc (6A). The pS187-H1.4 staining was also reduced (6J) as 
compared to the control (6G) and similar to the MCF7 cells and the HeLa-FLVP 
treatment appeared to have accumulated in some regions. Levels of pan-H1.4 and pS187-
H1.4 at the promoters of SOX2 and POU5F1 genes as a result of siH1.4 show a marked 












Figure 2.8. Panels A-L show immunofluorescent images of mESC cells treated with 
DMSO/FLVP for 1 hour and stained with pan-H1.4 (A-F) and pS187-H1.4 (G-L). pan-
H1.4 staining was slightly reduced after FLVP treatment (D) as compared to the control- 
DMSO treated (A). pS187-H1.4 staining was also reduced (J) as compared to the control 
(G) and similar to the MCF7 and HeLa cells appeared to have accumulated in a couple of 
regions. Levels of pS187-H1.4 at the promoters of SOX2 and POU5F1 genes as a result 
of FLVP treatment show a significant decrease when assessed by ChIP-PCR: graph 












Figure 2.9: Antibody validation by antigen adsorption and target knockdown.  
(A) Immunofluorescence panels A-C show immunostaining for pan H1.4 antibody in 
MCF7 cells. E-G show quenching of panH.4 staining as a result of antigen adsorption 
with recombinant H1.4 whole protein. Similarly, panels H-J show immunofluorescent 
signal for pS187-H1.4 antibody and panels J-L show quenching of the signal by antigen 
adsorption by specific peptide.  (B) ChIP-PCR using pS187-H1.4 antibody following 
knockdown of H1.4 at genes P2RY2 and PNRC1. P2RY2 is previously described to be 
induced by estradiol (E2) treatment and PNRC1 is previously described to be inhibited by 
E2 treatment.  (C) Western blot showing loss of specific H1.4 and pS187-H1.4 signal 







CHAPTER 3: INTERPHASE PHOSPHORYLATION OF H1.4 IS ASSOCIATED 
WITH TRANSCRIPTION ACTIVATION 
3.1 Introduction 
Histone H1 and the linker histones are members of a family of lysine rich proteins that 
have classically been identified as structural components of chromatin, playing a role in 
the formation of higher order chromatin structures associated with inaccessibility to 
transcriptional machinery [7, 73]. However, more recent studies suggest that H1 is 
functionally dynamic, and may have a gene-specific role in the regulation of gene 
expression [74-76]. Furthermore, several studies employing H1 depletion have shown 
that only a few genes are affected by reduction in histone H1 levels, and that the genes 
affected by H1 depletion may either be up- or down- regulated, arguing against a general 
repressive function [77].  
The H1 family is evolutionarily diverse, and present in non-allelic amino acid sequence-
variant forms in many metazoans. Humans express eleven H1 variants, of which seven 
are ‘somatic’; the rest are selectively expressed in germline tissues. Five of the seven 
somatic variants, namely H1.1, H1.2, H1.3 H1.4 and H1.5, are replication-dependent and 
are expressed predominantly during the S-phase of the cell cycle. These variants contain 
a more conserved amino acid sequence as compared to the replication-independent 
variants, namely H1.0 and H1.X. [78].  Metazoan H1 variants share a common tripartite 
structure containing a central globular domain (GD) that is flanked by shorter N-terminal 
domain (NTD) and a longer C-terminal domain (CTD). The GD sequence is highly 
conserved amongst species but there are extensive differences in the NTD and the CTD 




the association of H1 variants with chromatin is highly dynamic in vivo, and that the 
differences in the CTD regions may be key determinants of variant binding affinities and 
chromatin interaction dynamics [79].  
Like core histones, H1 CTDs and NTDs undergo several types of posttranslational 
modifications including methylation, acetylation, and phosphorylation. Based on older 
chromatography reports and more recent mass spectrometry, phosphorylation is observed 
to be most abundant modification, progressively increasing during the cell cycle and 
transiently peaking at mitosis [12, 47, 48]. These studies also revealed that different 
residues are phosphorylated during interphase and mitosis, and identified the specific 
sites of phosphorylation within the CTD.  Both CDK (cyclin dependent kinase) and non-
CDK motifs were identified as being phosphorylated. However, during interphase the 
serine-containing consensus CDK motifs (SPXZ- S: Serine P: Proline X: amino acid Z: 
Lysine (L)/arginine (R)) were the predominant sites of phosphorylation. These sites are 
also phosphorylated during mitosis, but during that time, threonine-containing CDK sites 
(TPXZ) and some non-CDK motifs are also phosphorylated [47, 80]. Several studies 
have suggested that the phosphorylation event changes the way H1 interacts with the 
chromatin. While some studies suggest that H1 phosphorylation results in its complete 
depletion from the chromatin [70, 74], others suggest that the interaction of H1 tails with 
the chromatin is simply weakened as a result of the excessive negative charge [81]. 
Together these studies suggest a more nuanced role for H1, and indicate that the 
phosphorylation event may be associated with transcriptional activation. However, since 
some of these studies did not use variant-specific tools, they were unable to pinpoint the 




Earlier studies from our lab, conducted in HeLa S3 cells, identified the predominant 
interphase phosphorylation sites in H1.2 and H1.4 as H1.2S173, H1.4S172 and H1.4S187 
[64]. Using novel, highly specific antisera developed for H1.4 phosphorylated at S187 
(pS187-H1.4), we showed that pS187-H1.4 is enriched at sites of transcription by RNAP 
I and II. The nuclear and nucleolar staining patterns obtained with our antisera against 
pS187-H1.4 and pS173H1.2/H15 was corroborated by a different group using their own 
pS173H1.2/H1.5 antibody [82]. In a more recent study, we showed that the global levels 
of H1 phosphorylation at H1.5 H1.5-Ser18 (pS18-H1.5), H1.2/H1.5-Ser173 (pS173-
H1.2/5) and pS187-H1.4 are subject to differential regulation and that pS187-H1.4 was 
associated with maintenance of pluripotency [71]. The accumulation of pS187-H1.4 
chromatin immunoprecipition (ChIP) signal, and the subsequent loss of that signal during 
differentiation at the promoters of the pluripotency genes, provided the first evidence that 
pS187-H1.4 is closely associated with the chromatin and is important for transcriptional 
activation. CDK9 was also identified in that study as the kinase responsible for this 
phosphorylation event [71]. 
Here, we provide the first genome-wide view of pS187-H1.4 dynamics using an inducible 
system – specifically, estradiol-responsive MCF7 cells. Using an affinity purified version 
of the pS187-H1.4 antibody, we show that pS187-H1.4 is strongly associated with the 
promoters of active genes. Further we show that these ‘active’ signals are quenched by a 
specific CDK9 inhibitor, Flavopiridol. We also show that pS187-H1.4 co-localizes with 
active RNAP II peaks, suggesting an interaction between the two proteins. In addition, 




Taken together, this data provides evidence towards a more nuanced role of H1 in and 
puts forth the possibility of a new layer of regulation within the accepted model of 
transcriptional activation.  
3.2 Genome wide distribution of pS187-H1.4 displays distinct patterns of enrichment 
A collection of unique, highly specific antisera were previously generated in our lab 
using synthetic phospho-peptides, and with the ability to recognize phosphorylation at 
single sites [64, 71]. These sites are either exclusive to individual human H1 variants or 
are shared between only two variants. In addition, ‘pan H1’ antisera were also raised 
using whole recombinant H1 variant protein that does not distinguish between 
phosphorylated forms [64]. While the phospho-H1 antisera provide a measure of 
phosphorylation between specific sites, the pan-H1 antisera provides a comparison of the 
H1 variant amounts present, regardless of its phosphorylation status. Evidence of the 
specificity of pS187-H1.4, pan-H1.4, pS18-H1.5 and pan-H1.5 have been described 
previously [63, 64].  
Although these antisera are highly specific, their efficiency for high throughput studies 
was limited.  Therefore, for this study, pS187-H1.4 and pan-H1.4 antisera were purified 
using a modified affinity chromatography approach to generate a collection of highly 
efficient set of H1 antibodies.  The antibodies were again tested for specificity using three 
different cell lines - MCF7, mESCs and HeLa.  Validation studies carried out in MCF7 
cells are shown in chapter 2. Since MCF7 cells have been extensively studied, a large 
amount of high throughput assay data are already available on public platforms for 




We used the purified pS187-H1.4 and pan-H1.4 antibodies to perform chromatin 
immunoprecipitation (ChIP) on MCF7 cells to reveal their genome-wide distribution.  
Peaks generated from the sequencing data were then associated with their nearest genes. 
The pan-H1.4 and the pS187-H1.4 peaks were averaged and aligned against a ‘typical’ 
canonical gene that was mathematically defined and normalized to have a gene body of 
10,000 bp and arranged such that all genes transcribe in the 5’ to 3’ direction (Figure 
3.1A). The peaks 2500bp region upstream and downstream of the promoter were binned 
differently (detailed in methods section) than the rest of the downstream gene body to 
highlight the enrichment patterns at the promoters and the relative depletion in the gene 
body. Here we see, that pS187-H1.4 peaks are enriched at the promoter region and 
depleted across the gene body. This association of pS187-H1.4 peaks with promoters was 
seen as significant with a log ratio of 2.85 (Table 3.1) when analyzed by the HOMER 
software (http://homer.ucsd.edu). HOMER identifies previously annotated functional 
genomic regions that are enriched in these peaks.  
In striking contrast to the enrichment pattern of pS187-H1.4, we observed that the pan-
H1.4 signal was depleted at promoters. This pattern of pan-H1.4 localization has been 
previously reported albeit using another antibody [23], thereby corroborating our data.  
In order to further identify the status of the promoters associated with pS187-H1.4 peaks, 
we used H3K4me3 ChIP-Seq data from a separate study conducted on MCF7 cells [86]. 
The H3K4me3 epigenetic mark has widely been associated with ‘active’ transcription 
state or transcription readiness of nearby promoters [87, 88]. We aligned the pS187-H1.4 
peaks and the H3K4me3 peaks around a normalized promoter and made an aggregate 




H3K4me3 peaks (Log p-ratio: 3.48). This suggests that pS187H1.4 peaks associates with 
‘active’ promoters. We made another interesting observation here where we see that a 
large portion of the pS187-H1.4 peaks were found to align with the H3K4me3 ‘dip’ [89] 
that is usually identified as a H3 depleted region or a Nucleosome Depleted Region 
(NDR). A statistical analysis of the pS187H1.4 peaks overlap with the H3K4me3-
associated NFR showed a higher log p-ratio: 3.9. We observe that it was 1.82 times more 
likely that the pS187-H1.4 peaks would be found in this H3K4me3 flanked NFR than a 
direct overlap of the two. In order to further confirm that the pS187H1.4 peaks were 
associated with ‘active’ promoters, we analyzed their overlap with another ‘active’ 
promoter mark; H3K27ac [86] (Figure 3.1C) and found them to have significant overlap 
(log ratio: 3.2). 
3.3 pS187-H1.4 peaks co-localize with promoter associated RNAPII 
Based on the location of the pS187-H1.4 peaks observed so far, we then analyzed the 
overlap of RNA Polymerase II (RNAPII), which is usually found to be proximal to the 
promoter of genes that are transcriptionally ready or active. We used ChIP- seq data 
derived from a different study [83]  conducted on MCF7 cells and generated aggregate 
plots with the average signal of RNAPII and compared that with the average signal of 
pS187-H1.4 at the promoters (Figure. 3.2A). Here we see that the pS187-H1.4 peaks at 
the promoter show a significant direct overlap with that of RNAPII (log ratio: 4.9). The 
aggregate plot also demonstrates an overlap of the averaged signals around the promoter. 
Therefore we analyzed the overlap of RNAPII with the pS187-H1.4 signal throughout the 
genome. Here we see that there is a positive correlation between the two. A scatter plot 




3.2B). Taken together, we see that pS187-H1.4 peaks have a distinct pattern of 
distribution where we see a strong association with ‘active’ promoters. However, in order 
to better understand the dynamics of pS187-H1.4 at the promoters, it was important to see 
if this signal would be enriched in a transcriptional-inducible system. 
3.4 Estradiol (E2) stimulation resulted in pS187-H1.4 peak enrichment   
We used the purified pS187-H1.4 and pan-H1.4 antibodies to perform chromatin 
immunoprecipitation (ChIP) on MCF7 cells that were treated with 20nM 17β-Estradiol 
(E2) for 30 minutes to ‘activate’ the estrogen-regulated network of genes, following 72 
hours of hormone starvation to monitor changes in global H1.4 phosphorylation [90].  
The estradiol response in different cell lines can vary to a point where some genes may be 
oppositely regulated [91]. For example, genes involved in cell proliferation like CDC2, 
CDC6, and Thymidine kinase 1 are induced by E2 in MCF7 cells, whereas in the similar 
E2 responsive breast cancer cell line, 231ER+, these genes are repressed [92]. These 
differences may be a result of different transcription factor and/or co-regulator contents in 
the different cells. However, to avoid such gene expression discrepancies we used data 
from independent studies limited only to MCF7 cells [93]. 
We conducted ChIP-seq in both untreated and E2-treated MCF7 cells with pS187-H1.4 
and pan-H1.4 antisera. The sequencing data was processed as described earlier in this 
section. We then used the peaks from pan-H1.4 and pS187-H1.4 before and after E2 
treatment to generate metagenome profiles to visualize their distribution across the 
genome with respect to a normalized gene (Appendix.B). The metagenome profile was 
created using the same binning and scaling parameters as was described for Figure 3.1.  




distribution with the 2830 E2 induced pS187-H1.4 peaks. We see that the E2 induced 
pS187-H1.4 peaks are enriched at the promoter of a typical gene as compared to the 
control trace representative of the pS187-H1.4 peaks.  This showed that pattern of pS187-
H1.4 distribution remains the same but can be further enriched as a result of hormonal 
induction. The depletion of the E2 treated pS187-H1.4 peaks in the gene body is similar 
to that seen with the untreated pS187-H1.4 peaks. The pattern of pan-H1.4 depletion at 
the promoters and gene bodies remained constant before and after E2 treatment. The 
overall increase in pS187H1.4 signal as a result of E2 induction (when represented in a 
metagenome profile is relatively small when visualized in the context of all occupied 
genes. This is expected since only ~15% of all genes are estradiol-responsive [83, 84, 94, 
95]. 
 Since the differential enrichment was seen at the promoter region, we then focused our 
study to that region for further analyses. We generated an aggregate plot with the average 
pS187-H1.4 peaks before and after E2 treatment, focused on 3000bp regions upstream 
and downstream of all TSSs to demonstrate the enrichment of pS187-H1.4 peaks at the 
promoter (Figure 3.3A). Here we see that both the pS187H1.4 peaks are most enriched at 
approximately 150bp from the transcription start site, i.e. towards the +1 nucleosome, 
where previous reports have found ‘paused’ polymerases to be bound [96, 97].  We also 
generated aggregate plots of the E2 treated pS187-H1.4 peaks to test overlap with 
H3K4me3, RNAPII and H3K27ac as was done in Figure 3.1 to demonstrate that the 
enrichment of these pS187-H1.4 peaks remained localized to the ‘active’ promoters 




Taken together, we see for the first time that the pS187-H1.4 signal is associated with 
‘active’ genomic regions and hints at a possible interaction with transcriptional 
machinery.  
In order to further understand this enrichment pattern as a result of hormone induction, 
we needed to focus our study on the pS187-H1.4 peaks that showed at least a 2 fold 
increase following E2 induction. 
3.5 2X differential pS187H1.4 signals enriched at promoters and can be quenched by 
CDK9 inhibition 
727 pS187-H1.4 differential peaks with at least a 2-fold increase in signal were observed 
as a result of E2 induction. This was visualized using an aggregate plot with the 
differential peaks aligned around a promoter, to reveal a similar pattern of distribution as 
in Figure.3.1B, but with a strong preferential enrichment at the promoter (Figure.3.4). 
Here we see a better resolution of signal at the promoters where the two-fold increase in 
pS187-H1.4 enrichment as result of E2 treatment over the untreated control is 
pronounced.  The pan-H1.4 signal was depleted at the promoters as compared to the 
pS187-H1.4 signal. We also tested the connection between CDK9 and H1.4 
phosphorylation in this context, by ChIP-seq conducted after a 1Hour treatment with 
CDK9-specific inhibitor, Flavopiridol (FLVP).  After this treatment, the pS187-H1.4 
signal at the promoters was significantly quenched (Figure.3.3B - green trace).  This data 
supports a previous report by our lab, in which pS187-H1.4 was identified as a bonafide 
substrate for the kinase activity of CDK9 [71] and further verifies the pS187-H1.4 signal. 
While the ‘metagenome’ profile and aggregate plots detect patterns of enrichment across 




genes, and thus may obscure critical differences at the level of individual or subsets of 
individual genes.  Here, genes within 1Kb of the pS187-H1.4 differential peaks were 
identified and used to further focus our study. 710 candidate genes were found to be 
associated with atleast 2X fold increase in pS187-H1.4 signal as a result of E2 treatment.  
We then used the GREAT platform (http://great.stanford.edu ) to reveal the correlation of 
the E2 induced pS187-H1.4 enriched genes with previously established functional 
annotations (Table 3.2). The top ten annotation correlations with their p-value is listed 
from the MSigDB perturbation category. This ontology category contains gene sets that 
represent gene expression signatures of genetic and chemical perturbations. Here we 
observed, that the strongest associations of  pS187-H1.4 peaks are with gene sets that 
were up-regulated as a result of estradiol addition in MCF7 cells, other breast cancer cell 
lines and even some breast tumor samples under a variety of conditions and with varying 
longer times of E2 treatments.  This suggests that pS187-H1.4 strongly associates with 
bonafide E2 up-regulated genes that are possibly required to be expressed to continually 
maintain or are a part of the downstream estrogen-regulation network. 
In order to visualize this estradiol induced pS187H1.4 enrichment at an individual gene, 
we used the UCSD genome browser (https://genome.ucsc.edu) (Figure.3.4A). We 
selected the Flotilin1 (FLOT1) gene from the list of candidate genes that associated with 
the 2X pS187-H.14 differential peaks. Here we see, the FLOT1 promoter is clustered 
very close to the promoter of IER3.  Both promoter regions show a basal level of pS187-
H1.4 signal. In contrast, after E2 stimulation pS187-H1.4 ChIP signals were markedly 
increased. In addition to observing an increase in the pS187-H1.4 signal as a result of 




of H3K4me3 as was seen in figure 3.1B. In order to demonstrate the veracity of the 
pS187-H1.4 signal, we also added the track showing pS187-H1.4 signal quenched as a 
result of pre-treatment with CDK9 inhibitor- Flavopiridol.  Browser views of two more 
representative genes, TFF1 and KRT8, demonstrating the increase in pS187-H1.4 signal 
as a result of estradiol treatment, quenched pS187-H1.4 signal as a result of FLVP 
treatment, co-localization of signal between H3K4me and active RNAPII can be found in 
the Appendix C. 
To confirm and quantitate the genome-wide data, we focused on genes that showed an 
increase in promoter pS187-H1.4 signal as a result of E2 induction in ChIP-seq, and 
performed ChIP-qPCR to verify this pattern on an individual gene level. FLOT1, TOB1 
and TFF1 genes were chosen based to confirm E2 based changes (Figure 3.4B-E). We 
also included P2RY2 and its estrogen receptor binding site approximately 20kb upstream 
of the promoter; ERBS1 which based on previously published GRO-sequencing data 
show that these genes undergo transcription upregulation in response to E2 treatment [83, 
84]. Primers overlapping the promoter regions of these genes were designed to this mix 
of genes to independently verify that not only genes identified in this study but also, 
previously identified E2 induced genes showed the pS187-H1.4 enrichment pattern at the 
promoter as described in Figure.3.1. FLOT1, TOB1, TFF1, P2RY2 and ERBS1 all 
showed a significant increase in the pS187-H1.4 ChIP signal at their promoters. To 
confirm and quantitate the loss of pS187-H1.4 signal as a result of FLVP treatment, 
P2RY2 and ERBS1 were used as a representative pair. The quenching of the signal 
observed as a result of CDK9 inhibition supports the idea that the signal observed was in 




ACTG (Appendix C) remained relatively unchanged as a response to E2 treatment and 
was reduced as a result of FLVP treatment (Appendix C). Minor changes observed might 
be attributed to their involvement in cytoskeletal rearrangements as a result of E2 
induction as previously described [98].  
We also performed RT-qPCR on candidate genes derived from this study to verify their 
individual gene expression levels in our experimental system (Figure. 3.5A-D). We 
confirmed that FLOT1, TOB1, TFF1 and SMAD7 expression was significantly induced, 
with a two-fold increase in signal, as a result of estradiol addition. This correlates with 
ChIP-qPCR data (Figure.3.4), since pS187H1.4 was found to be enriched at the 
promoters of these genes as a result of E2 treatment. We also tested the role of H1.4 
directly in the E2-activation of these genes by knocking down expression of H1.4 with 
RNAi.  The induction of all of these E2-responsive genes was lost as a result of H1.4 
knockdown, suggesting that H1.4 is important for the E2 induced activation of these 
genes. 
Taken together, the data presented here shows for the first time that a phosphorylated 
form of a linker histone variant i.e pS187-H1.4 is enriched at ‘active’ genomic regions, 
specifically promoters, when transcription is induced. This is in contrast to previous 
findings [12, 78] that reported a depletion of H1 by phosphorylation at transcriptionally 
‘active’ sites.  
3.6 pS187-H1.4 enrichment at previously identified estradiol responsive genes 
In a study by Stendner et. al. 2007, 196 genes were identified as regulated by estrogen in 
the MCF7, where genes were either stimulated or repressed by E2.  This study also 




critical component of the hormone-induced proliferative response. To ensure that the 
pS187-H1.4 enrichment we see, is in fact associated with previously identified E2 
responsive genes, we used the estrogen-responsive genes identified in the Stendner et.al. 
study, along with the locations of estrogen receptor and E2F binding sites, to filter our 
pS187-H1.4 enrichment study. Aggregate plots were generated to visualize the pattern of 
enrichment around the 196 identified E2-responsive genes (Figure 3.6). This E2-
responsive set of genes reproduced the trend for analysis of genome-wide peaks as that 
seen in Figure. 3.3A, with the pS187-H1.4 enrichment at the promoter with the peak 
shifted towards the +1 nucleosome. This trend shows that the phosphorylation of H1.4 is 
not only associated with active promoters, but may be involved in the early response in 
the activation of genes as evidenced by the association of pS187H1.4 signal with verified 








3.7 Figures and Tables 
 
 
Figure 3.1 Global distribution of pS187-H1.4 and pan-H1.4 in MCF7 cells 
Figure 3.1 (A): A metagenome profile generated with pS187-H1.4 and pan-H1.4 ChIP-
sequencing data to study enrichment across a typical gene. The gene body was 
mathematically defined and normalized to 10kb. +2.5kb and -2.5kb regions relative to the 
promoter were binned at 100bp. 2.5kb to 10kb represents a normalized gene body binned 




Figure 3.1 (Cont.) enrichment of the pS187-H1.4 signal (orange trace). There was a 
depletion of the pS187-H1.4 and the pan-H1.4 (navy blue trace) signals along the gene 
body.  (B): Aggregate plot centered on the promoter showing average pS187-H1.4 signals 
and its overlap with H3K4me3 signals. The signal was aligned +2Kb and -2Kb relative to 
the Refseq TSSs H3K4me3 was plotted on a secondary axis (label on right side). The 
direct overlap of peak was calculated as a log ratio of 3.48.  H3K4me3 flanked predicted 
NDR region is highlighted in blue. The overlap of the pS187-H1.4 with this NDR region 
is 3.94. (C): Aggregate plot centered on the promoter showing average pS187-H1.4 
signals and its overlap with H3K27ac signals. H3K27ac was plotted on a secondary axis 
(label on right side). The direct overlap of peak was calculated as a log ratio of 4.94. 
 







Table 3.1: Summary table of pS187-H1.4 peak correlations with genomic regions and 





Figure 3.2: pS187-H1.4 associates with RNAPII. (A) Aggregate plot comparing average 
RNAPII (Green) and p187-H1.4 (Orange) peaks near promoter regions. The signal was 
aligned +2Kb and -2Kb relative to the Refseq TSSs. RNAPII plotted on a secondary axis 
(label on right side of graph).  Direct overlap ratio calculated as log ratio: 4.94. (B) 
Correlation scatter plot of pS187-H1.4 and RNAPII peak overlap throughout the genome. 





Figure 3.3: Estradiol induced pS187-H1.4 peaks near promoter. (A) Aggregate plot with 
average pS187H1.4 peaks before (Orange) and after (Blue) estradiol (E2) treatment. The 
signal was aligned +3Kb and -3Kb relative to the Refseq TSSs Following estradiol 
treatment, pS187-H1.4 is enriched. Highest signal of pS187-H1.4 shifted towards the 




Figure3.3 (Cont.)  
estradiol treatment is also seen. Depletion of signal at promoters is seen.  (B) Aggregate 
plot of average 2X differential pS187-H1.4 peaks near the promoter region before 
(Orange) and after (Blue) estradiol treatment. Following estradiol treatment, distinct 
enrichment of pS187-H1.4 over the untreated is observed. The signal was aligned +2Kb 
and -2Kb relative to the Refseq TSSs. CDK9 inhibitor treatment – Flavopiridol quenches 











Table 3.2: GREAT associations made with 2X differential pS187-H1.4 signal associated 





Figure 3.4: pS187-H1.4 2X differential signal verified on an individual gene level. (A) 
UCSC genome browser shot showing pS187-H1.4 signal before and after (-/+) estradiol 





Figure 3.4 (Cont.) 
and after estradiol treatment.  The green track shows the pS187-H1.4 signal quenched as 
a result of FLVP treatment. H3K4me3 track in red is included to show ‘active’ state of 
genes. (B) ChIP-qPCR conducted with pS187-H1.4 antibody to verify changes on an 
individual gene level. Changes in pS187-H1.4 enrichment as a result of E2 addition   
shown at FLOT1, TOB1, TFF1 and P2RY2 promoters. All four genes show a significant 
increase in pS187-H1.4 enrichment as a result of E2 addition. (*p-value<0.01, **p-
value<0.001) (C) ChIP-qPCR conducted with pS187-H1.4 antibody to show pS187-H1.4 
enrichment at the P2RY2 gene promoter and its estrogen receptor binding site (ERBS1) 
that is ~20kb upstream of the promoter. The consequent loss of enrichment as a result of 
FLVP treatment is also shown. Rabbit immunoglobulin (rIg) used as a control for non-
specific binding. Vehicle treated (DMSO) samples show an increase in pS187-H1.4 
signal as a result of E2 addition. FLVP treated samples show an impaired ability of 















Figure 3.5: RT-qPCR to show importance of H1.4 in gene expression. Signals shown as a 
relative fold change in expression. Candidate genes from our ChIP-seq study were 
selected to show that E2 treatment led to an increase in gene expression. This coincides 
with the increase in pS187-H1.4 ChIP-PCR signal described in Figure.4B. siLuciferase 
(Control) was compared to siH1.4 to reflect loss of gene expression at H1.4 depleted 













Figure 3.6: pS187-H1.4 at early responding E2 induced genes. 196 genes previously 
identified as being early targets of estrogen induction were analyzed for pS187-H1.4 
signal at their promoters. Aggregate plot with average pS187-H1.4 signal before (orange) 
and after (blue)   estradiol treatment plotted centered at refseq TSSs. A correlation ratio 





3.8 Materials and methods 
3.8.1 Cell culture 
MCF7 cells were a kind gift from Dr. Katzenellenbogen (UIUC). They were grown in 
RPMI 1640 media supplemented with 5% fetal bovine serum (FBS) and 1% Penicillin-
streptomycin and subcultured by trypsin treatment followed by seeding at 1.5× 106 cells 
per 10cm plate (0.25%).  Before use, the cells were subjected to 72 hours estradiol 
starvation by growing in phenol-red free RPMI1640 supplemented with charcoal dextran 
treated FBS (CD-FBS). Following starvation, the cells were induced with 20nM beta- 
estradiol (E2) dissolved in ethanol for 30 minutes before harvesting.  In case of drug 
treatments, the cells were pre-treated with Flavopiridol (NIH AIDS Reagent Program) or 
THZ1 (ApexBio) for 1Hr before E2 induction to selectively inhibit CDK9 and CDK7 
respectively.  
3.8.2 siRNA knockdown 
siRNA treatments were conducted using Lipofectamine RNAiMAX (Invitrogen) and 
H1.2/H1.4, H1.4, CDK9, CDK7siRNA  according to manufacturer’s protocol. The cells 
were seeded the day prior to transfection to achieve 50-60% confluency at the time of 
treatment. siRNA and lipofectamine were diluted in Opti-MEM (Gibco), mixed, 
incubated for 5 mins and the complexes were then added directly to the cells now 
growing in phenol-red free, CD-FBS Media to allow estrogen starvation along with 
siRNA knockdown simultaneously. After 72 hours, the cells were E2/ ethanol for 30 






3.8.3 Chromatin Immunoprecipitaiton 
Chromatin immunoprecipitation was performed using protocols described before [71] 
with minor adjustments. Briefly, cells were cross-linked using methanol-free 
paraformaldehyde (Thermo Fisher Scientific) for 8 minutes quenched by 125mM final 
concentration Glycine for 10 minutes. The cells were then washed 3 times with cold PBS 
before scraping and resuspension in ChIP lysis buffer supplemented with protease and 
phosphatase inhibitors. Chromatin was then sonicated using repeated cycles for 25 
minutes in the BiorupterTM UCD-200 (Diagenode, Liège, Belgium) sonicator to a mean 
sheared length of ~500kb. Following centrifugation, the supernatants were diluted tenfold 
using ChIP-dilution buffer. 1ml aliquots representative of 1.5- 2× 106 cells were then 
incubated with primary antibody overnight at 4 ֯C. The antibody-chromatin complexes 
were then incubated with 50μl BSA-blocked Dynabeads (Invitrogen) for 4H at 4 ֯C and 
then collected using a magnetic separator. Following sequential ChIP-Buffer and TE 
Buffer washes, the beads were eluted using 200μL freshly prepared elution buffer. NaCl 
was added to these eluates (final conc. 200mM) and incubated at 65 ֯C overnight to 
reverse crosslink the immunocomplexes. Following RNAseA and Proteinase K digestion, 
the DNA was then purified using Phenol/Chloroform extraction and then precipitated 
using glycogen as a carrier. The precipitated DNA was then dissolved in TE buffer and 
used for qRT-PCR or sequencing. 
3.8.4 Quantitative Real Time-PCR (qRT-PCR) 
For expression analyses, RNA was extracted from cells using the trizol extraction method 
as described before and further purified using the Qiagen DNA purification kit. cDNA 




scientific) according to manufacturer protocol. cDNA or ChIP products  were used for 
qRT-PCR with SYBR-Green Mix (Applied Biosystems) and primers listed in Appendix 
D. 
 3.8.5 Sequencing and Bioinformatic analysis 
ChIP products were used to prepare libraries using a kit from KAPA Biosystems. 
Manufacturer protocols were followed for sheared DNA size 500-700Kb. Quality control 
of libraries was conducted using a bioanalyser and then sequenced using the Illumina-
Hiseq 4000.  
Sequence data were mapped with Bowtie2 [99] to the UCSC hg19 genome, using default 
settings. Mapped sequence data were analyzed for peaks using HOMER (Hypergeometric 
Optimization of Motif Enrichment) v4.10 [100]. Samples were converted into tag 
directories, and QC was performed using read mapping and GC bias statistics. Histone 
peaks were then called from the Tag Directories with default factor settings, except local 
filtering was disabled (-L 0), peak size was set at 200bp (-size 200) and minimum 
distance between peaks was set at 150 (-min. dist. 150), to increase the sensitivity of the 
peak calling and identify individual subunits of multihistone peaks. After peak calling, 
peak files were annotated to the human hg19 genome using HOMER’s annotation script 
to assign peaks to genes, and associate peaks with estrogen responsive differential genes 
identified elsewhere by Gro-Seq [83, 101]. BigWiggle pileup files were generated using 
HOMER’s makeBigWig.pl script with default settings and uploaded to a UCSC Genome 
Browser track hub for visualization (http://stubbslab-ucsc.igb.illinois.edu/ucsc/public/). 
Differential chromatin peaks were identified using the HOMER getDifferentialPeak.pl 




significance cutoff of 1 x 10-4. Genes annotated nearby differential H3K27ac peaks were 
submitted for GO analysis to DAVID and GREAT [101, 102]. Metagenome profiles were 
generated using the HOMER makeMetaGenomeProfile script using default settings.  
Aggregate Plots were generated using the HOMER annotatePeaks script with size set to 
4000bp and binning set to 10bp.    
Two biological replicates of pS187-H1.4 and pan-H1.4 ChIP-sequencing was performed. 
The efficiently of replicate 1 was better than replicate 2 however, the peak enrichment 
patterns agreed closely (Appendix. C). Data from the first replicate was used to generate 















CHAPTER 4: DISCUSSION 
4.1 pS187H1.4 enrichment at promoters mark active genes 
Previous attempts to understand the functions of histone H1 have involved mapping the 
distribution of all H1 variants together across the genome, under the assumption that all 
of the H1 variants were interchangeable and redundant in function.  However, like core 
histones, H1 variants also undergo distinct post-translational modifications that afford 
differential functionality to these proteins. Among these modifications, phosphorylation 
is most abundant [12, 26].   However, the lack of specific antibodies has restricted the 
exploration of functions for these common H1 histone modifications.   
In the present study, we have addressed this gap in knowledge by employing a novel 
antibody that allowed the identification of genome-wide binding sites for a specific 
phosphorylated version of variant H1.4, pS187-H1.4.  Early studies show that the 
sequence of human H1.4 shares a 93.5 sequence identity with that of its mouse ortholog 
[11, 27], much higher than was observed for other variants indicating the functional 
significance of H1.4. Another report showed that the loss of H1.4 in T47D breast cancer 
cells resulted in cell death [77].  
This variant undergoes various post-translational modifications (PTMs), such as K26 
methylation[34] which allows binding of HP1 and subsequent heterochromatin function, 
and Gcn5-mediated H1.4K34Ac [38], which works to activate transcription by 
facilitating the binding of chromatin remodelers and recruitment of transcription factors.  
Furthermore, ChIP-qRT-PCR studies from our laboratory in Hela, NT2 and mESC cells 
have implicated pS187-H1.4 in transcriptional activation, showing enrichment of this 




the number of studies looking into PTMs, there is currently no genome- wide study 
describing the predominant interphase phosphorylation sites. With this study we provide 
the first genome wide evidence of functions of pS187-H1.4, in the context of estradiol 
(E2) regulation. Earlier reports have described the estrogen response as being carried out 
through estrogen receptor isoforms (ERα or ERβ) dimerizing with 17β estradiol and 
binding to specific motifs in the DNA to elicit a transcriptional response [103-105]. In 
this well-studied system of rapid signaling it is novel to observe that a variant of the 
linker histone - a family of protein usually associated with repression, enriched at the 
promoters – specifically binding to the transcription start sites (TSSs) of ERα/β-E2-
activated genes.  Data presented here strongly support this association and suggests a 
strong possibility that the H1.4, in its phosphorylated form, may add another layer of 
transcriptional control that has not so far been identified. Surprisingly, pS187H1.4 
binding is enriched in nucleosome-free regions that are known to harbor active binding 
sites for transcriptional control intermediaries, co-regulators, and even RNAPII [83, 106, 
107]. Especially given the observation that there is a significant direct overlap of the 
pS187-H1.4 and RNAPII and genome wide positive correlation of the two, the possibility 
of direct/indirect association with transcriptional regulators is now open for investigation.   
In a previous study by Liao et al, [71] CDK9 was identified as the primary kinase 
responsible for the phosphorylation of S187H1.4. In this study, we also showed that on a 
genome level the pS187-H1.4 signal at the TSSs is quenched when treated with the 
CDK9 inhibitor, Flavopiridol (Figure.3). The CDK9 kinase is a part of the PTEF-b 
complex which has been shown to be responsible for the activation of RNAPII by 




depletion.  This is followed by Ser5 and DRB-sensitivity Inducing Factor (DSIF) 
phosphorylation, such that it becomes a positive elongation factor and travels with the 
polymerase [108]. Despite the obvious importance of DSIF and NELF as rate-limiting 
factors for PolII, growing evidence suggests that there may be additional factors may 
contribute to this regulation, including Gdown1 and TFIIF [109, 110].  With this study, 
we provide evidence that not only is pS187-H1.4 a substrate of the same kinase that is 
involved in the regulation of PolII, but it also significantly occupies the nucleosome-
depleted regions as the ‘paused’ PolII throughout the genome. Together with evidence 
that pS187-H1.4 signals appears to accumulate at a predicted +1 nucleosome location 
where ‘elongating polymerases’ are known to be found [111] ,  we speculate that H1.4 
may be a novel factor required in the ‘activation’ of transcriptional elongation or may 
even be involved in ‘ priming’ the chromatin to allow transcriptional elongation by 
RNAPII.  
4.2 Genome wide distribution of pS187-H1.4 reveals possible interaction with multiple 
transcriptional regulatory pathways 
The association of pS187-H1.4 with features across the genome and particularly 
promoters, strengthens the hypothesis that H1.4 is important for the activation of genes 
via the RNAPII regulatory pathway. However, it is noteworthy to observe that there a 
strong enrichment of pS187-H1.4 observed in CpG Islands which are known to mainly 
contain sites of active transcription (Table 3.1). The regulation of these chromatin regions 
is noteworthy in that it depends on methylation state of the DNA and activity and /or 
recruitment of polycomb factors. In special relevance to this study, CpG islands are 




113]. We also observed that pS87H1.4 is strongly associated with non-coding RNAs 
(ncRNAs) and small nucleolar RNA (snRNA), both of which have different regulatory 
mechanisms in their response to gene activation stimuli. The role of ncRNAs in the form 
of lncRNAs like HOTAIR, MIAT, and H19 in estradiol response have only recently been 
described. In this context, the ncRNAs have been shown to regulate transcription by 
interacting with and guiding various chromatin modifying complexes like Polycomb-
repressive complex 2 (PRC2) and Lysine-specific demethylase 1 (LSD1) [114]. 
Similarly, a distinct mechanism of activation is employed by snRNAs.  
Together, this suggests that pS187H1.4 may be able to interact with multiple different 
transcriptional regulators, all with the final outcome of transcription activation. This 
suggests that globally pS187H1.4 may be a versatile factor with the capability of 
interacting with various transcription regulatory components. Although this study was 
focused on the estradiol based response system as a model, we observed a basal level of 
pS187-H1.4 proximal to the promoters. Together these data suggest that pS187H1.4 may 
play a more global role in the regulation of transcription.  
4.3 Conclusions 
Since H1 has been largely regarded as a general repressor, the progress toward 
understanding the function and the mechanisms of action of individual H1 family 
members has been slow. Further, the paucity of appropriate ChIP-grade antibodies has 
also been a limiting factor.  However, our novel, highly specific antibodies have allowed 
us to describe the role of pS187H1.4 in transcriptional activation for the first time, 
opening up a new area of study and suggesting that the roles of other specific H1 variants 




 In order to further elucidate the effect of H1.4 phosphorylation on gene activation, the 
mechanism of action must be tested.  In particular, the extent and nature of downstream 
effects must be assessed in cases where the phosphorylation event is prevented. 
Identifying the mechanism of CDK9 recruitment to this H1.4 will also yield an insight 
into the nature of its activity with regard to RNAPII regulation.   However, these studies 
raise important issues regarding the functions of H1.4 variants that suggest broad 
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APPENDIX A: H1 VARIANT LOCALIZATION IN DIFFERENT CELL TYPES 














A.2 H1 variants distribution in C2C12 cells before and after differentiation. 
 
 





APPENDIX B: pS187-H1.4 CO-LOCALIZATION WITH NUCLEAR ELEMENTS 
B.1 pS187-H1.4 associated with speckle-like nuclear regions/ transcription factories in 





B.2 pS187-H1.4 associated with speckle-like nuclear regions/ transcription factories in 
C2C12 cells
 
















B.5 Drug treatment to observe pS187-H1.4 localization changes in NT2 cells 
 
 
pS187-H1.4 co- staining with nucleolar marker-Fibrillarin in undifferentiated NT2 cells 













APPENDIX C: pS187H1.4 GENOMIC DISTRIBUTION AFTER E2 
TREATMENT 
C.1 pS187-H1.4 and pan-H1.4 metagenome and aggregate plots showing H1.4 




















APPENDIX D:  BROWSER SHOTS DEMONSTRATING AGREEMENT OF TRENDS 
BETWEEN BIOLOGICAL REPLICATES 








D.2 Browser shot of FLOT1 demonstrating signal agreement between biological 
replicates 
 
 
 
